Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 3Multiple Myeloma 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1

Interventions

Dexamethasone 242Lenalidomide 147daratumumab 125Bortezomib 102pomalidomide 88Calcium Dobesilate 76carfilzomib 75Cyclophosphamide 71Specimen Handling 42isatuximab 41Biopsy 40belantamab mafodotin 37fludarabine 36Magnetic Resonance Spectroscopy 35talquetamab 29Melphalan 28dexamethasone acetate 27dexamethasone 21-phosphate 27auricularum 26iberdomide 25ixazomib 22fludarabine phosphate 22selinexor 21elotuzumab 21Whole-Body Irradiation 14X-Rays 13tocilizumab 12venetoclax 11Mycophenolic Acid 10trametinib 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Multiple Myeloma × Pneumococcal Vaccines × 1 year × Clear all
NCT03376477 2025-08-27

Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Terminated
24 enrolled 8 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡